DECTOVA

This brand name is authorized in Austria, Estonia, Finland, France, Croatia, Ireland, Lithuania, Netherlands, Poland, United Kingdom

Active ingredients

The drug DECTOVA contains one active pharmaceutical ingredient (API):

1 Zanamivir UNII L6O3XI777I - ZANAMIVIR

Zanamivir is a selective inhibitor of neuraminidase, the influenza virus surface enzyme. Neuraminidase inhibition occurred in vitro at very low zanamivir concentrations (50% inhibition at 0.64nM–7.9nM against influenza A and B strains). Read about Zanamivir

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
DECTOVA Solution for infusion	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J05AH01	Zanamivir	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AH Neuraminidase inhibitors
Discover more medicines within J05AH01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1795754, 1874246
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 395010
Country: FR	Base de données publique des médicaments	Identifier(s): 64427189
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 378891
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1087663
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 199818
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100420087